Health. Quality. Life.
hu en

Our Results

Despite the recession and the harsh economic conditions both in our Hungarian and export markets, Egis Pharmaceuticals PLC closed the 2012/2013 financial year with outstanding success and our growth has been dynamic for years. Our net sales revenue was HUF 136 billion in the 2012/2013 financial year (lasting from 1 October 2012 to 30 September 2013) with a 2% increase compared to the previous financial year. 79% of our revenue derived from export with significant sales performance in our key export markets: EUR 179 million in Russia and other CIS-countries, EUR 125 million in Central and Eastern Europe. In our domestic market, Hungary Egis Pharmaceuticals PLC has traditionally been one of the market leaders. Our company ranks third both on the basis of the number of packages sold in the Hungarian market and among the generic pharmaceutical companies.

In accordance with our strategic goals, the number of our products has been continuously growing. While in the previous years our company had 3-5 product launches yearly on average, we launched 8 new products in our markets in the 2012/2013 financial year. At the end of the financial year we had 354 domestic registrations and 2,673 abroad.

Three therapeutic areas are in the focus of our R&D activities: the cardiovascular, the central nervous and the respiratory systems, which altogether account for 74% of our sales revenue. Although we continue to place the main emphasis on these areas, we continuously open towards new therapeutic areas.

The most important key to our competitiveness and our future success is innovation, to which we dedicate an outstanding amount every year. In the 2012/2013 financial year we spent 9.3% of our sales revenue, HUF 12.6 billion on research and development.

Our performance is the joint achievement of our more than 4,000 colleagues working in Hungary and at our affiliates and subsidiaries in various parts of the world.